Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chiesi Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT00782535
First received: October 29, 2008
Last updated: November 17, 2011
Last verified: November 2011
  Purpose

The purpose of this study is to characterize the dose-response profile of peak and trough FEV1 after single dose administrations of carmoterol in patients with COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: CHF 4226 pMDI
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study

Resource links provided by NLM:


Further study details as provided by Chiesi Pharmaceuticals Inc.:

Primary Outcome Measures:
  • FEV1 [ Time Frame: T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • serum potassium [ Time Frame: pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period ] [ Designated as safety issue: Yes ]
  • serum glucose [ Time Frame: pre dose and 1, 4, 6 and 24 hrs post dose for each treatment period ] [ Designated as safety issue: Yes ]
  • plasma concentrations of CHF 4226 [ Time Frame: pre dose and 15 minutes and 2 hours post dose for each treatment period ] [ Designated as safety issue: No ]
  • urinary excretion of CHF 4226 [ Time Frame: pre dose and 0-24 hrs post dose for each treatment period ] [ Designated as safety issue: No ]
  • FVC [ Time Frame: T-1hr, T-10min, and 15 and 30 minutes, 1, 2, 3, 23 and 24 hours for each treatment period ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: December 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A
Single therapeutic dose of CHF 4226 pMDI
Drug: CHF 4226 pMDI
Inhaled solution, single therapeutic dose
Experimental: Treatment B
Single therapeutic dose of CHF 4226 pMDI
Drug: CHF 4226 pMDI
Inhaled solution, single therapeutic dose
Experimental: Treatment C
Single supratherapeutic dose of CHF 4226 pMDI
Drug: CHF 4226 pMDI
Inhaled solution, single supratherapeutic dose
Experimental: Treatment D
Single supratherapeutic dose of CHF 4226 pMDI
Drug: CHF 4226 pMDI
Inhaled solution, single supratherapeutic dose
Placebo Comparator: Treatment E
Single dose of placebo
Drug: Placebo
Inhaled solution, single dose of placebo

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has signed an IRB approved Informed Consent form and the written informed consent was obtained prior to any study-related procedure(s)
  • Patient is a male or non-pregnant female, 40 -75 years old, inclusive
  • Patient has a current or past cigarette smoking history of at least 15 pack-years
  • Patient has a clinical diagnosis of COPD in accordance with the recommendations of the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
  • Patient meets the following requirements after an FEV1 albuterol reversibility test (i.e., 30 minutes following 400µg (metered dose) albuterol MDI):
  • FEV1/FVC < 70%
  • FEV1 is at least 0.9L
  • FEV1 30% - 80%, inclusive, of patient's predicted normal value
  • ∆FEV1 > 5% of pre-albuterol value
  • If ∆FEV1 </= 5% of pre-albuterol value, then this requirement must be met after retesting during the run-in period, at least 24 hours prior to Visit 2.

Exclusion Criteria:

  • Patient has a history of asthma
  • Patient has a blood eosinophil count > 500/µL
  • Patient has a history of allergic rhinitis or atopy
  • Patient had a COPD exacerbation or a lower respiratory tract infection within 8 weeks prior to screening, or during the run-in period, that resulted in the use of an antibiotic, or oral or parenteral corticosteroids
  • Patient is on an inhaled corticosteroid that has been initiated, or the effective dose has been changed, within 4 weeks prior to screening or during the run-in period
  • Patient has an uncontrolled cardiovascular (e.g., uncontrolled hypertension), respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g., uncontrolled diabetes mellitus) or other disease, or any condition that might, in the judgment of the Investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study
  • Patient has clinically significant abnormal routine hematology (e.g., anemia) and/or clinical chemistry value(s).
  • Patient has a history of coronary artery disease, cerebrovascular disease, cardiac arrhythmias
  • Patient has lung cancer or a history of lung cancer
  • Patient has active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of the skin is acceptable.
  • Patient has a serum potassium value ≤ 3.5 mEq/L or > 5.5mEq/L and/or a fasting serum glucose value ≥ 140 mg/dL
  • Patient has an abnormal QTcF interval value in the Screening visit ECG test (i.e., > 450 msec in males or > 470 msec in females)
  • Patient has developed Cor Pulmonale
  • Patient is receiving long term oxygen therapy, i.e., > 16 hours/24-hour period, every day, unless residing at an elevation > 4000ft
  • Patient has used any of the following medications prior to Screening and has not met the specified minimum washout period:
  • Long acting anti-cholinergic agent (i.e., tiotropium): 7 days
  • Short acting anti-cholinergics: 8 hours
  • Fixed combinations of β2-agonists and inhaled corticosteroids: 48 hours
  • Fixed combinations of an anti-cholinergic and short acting β2-agonist: 8 hours
  • Long-acting β2-agonists: 48 hours
  • Short acting β2-agonists: 6 hours
  • Theophylline and other xanthines: 1 week
  • Parenteral or oral corticosteroids: 1 month
  • Patient has taken any non-permitted medication
  • Patient has received a live-attenuated virus vaccination within two weeks prior to screening or during the run-in (inactivated Influenza vaccination is acceptable provided it is not administered within 48 hours prior to Screening)
  • Patient has a known intolerance/hypersensitivity to β2-adrenergic agonists, propellant gases/excipients
  • Patient is pregnant or lactating female, or female physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL OR are using one or more of the following acceptable methods of contraception:
  • surgical sterilization (e.g., bilateral tubal ligation, hysterectomy)
  • hormonal contraception (implantable, patch, oral)
  • double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)
  • Patient is male and does not agree to use a medically acceptable contraceptive (abstain from sexual intercourse, or use a condom with spermicide), or has not had a vasectomy at least 6 months prior to study participation, unless their sexual partner is not of child-bearing potential
  • Patient is mentally or legally incapacitated
  • Patient has participated in another investigational study within 30 days prior to screening
  • Patient abuses alcohol or other substances
  • Patient does not maintain regular day/night, waking/sleeping cycles (e.g., night shift worker)
  • Patient is potentially non-compliant or unable to perform required outcome measurements of the protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00782535

Locations
United States, Florida
University Clinical Research DeLand, LLC
DeLand, Florida, United States, 32720
United States, Kentucky
Commonwealth Biomedical Research, LLC
Madisonville, Kentucky, United States, 42431
United States, Ohio
New Horizons Clinical Research Center
Cincinnati, Ohio, United States, 45242
United States, Oregon
Clinical Research Institute of Southern Oregon, PC
Medford, Oregon, United States, 97504
United States, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
Sponsors and Collaborators
Chiesi Pharmaceuticals Inc.
Investigators
Principal Investigator: Gregory M Gottschlich, MD New Horizons Clinical Research
  More Information

No publications provided

Responsible Party: Chiesi Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT00782535     History of Changes
Other Study ID Numbers: CCD-0810-PR-0001
Study First Received: October 29, 2008
Last Updated: November 17, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 16, 2014